Thalia Therapeutics PLC
0GO
Company Profile
Business description
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.
Contact
C/o Arch Law Limited
8 Bishopsgate
Huckletree Bishopsgate
LondonEC2N 4BQ
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,725.10 | 33.40 | -0.38% |
| CAC 40 | 7,846.55 | 102.63 | 1.33% |
| DAX 40 | 22,957.08 | 320.17 | 1.41% |
| Dow JONES (US) | 46,429.49 | 305.43 | 0.66% |
| FTSE 100 | 10,106.84 | 141.68 | 1.42% |
| HKSE | 24,983.12 | 352.83 | -1.39% |
| NASDAQ | 21,929.82 | 167.93 | 0.77% |
| Nikkei 225 | 53,552.81 | 196.81 | -0.37% |
| NZX 50 Index | 13,006.73 | 77.43 | 0.60% |
| S&P 500 | 6,591.90 | 35.53 | 0.54% |
| S&P/ASX 200 | 8,523.80 | 23.20 | -0.27% |
| SSE Composite Index | 3,909.16 | 22.68 | -0.58% |